Vol. 6 No. 1 (2019): January-December 2019

Review

Cost per response/remission in biologics available in Italy for the treatment of TNF-α inhibitors-naïve patients with ulcerative colitis

Matteo Ruggeri, Francesca Romana Rolli
- PDF
SIR-Spheres® Y-90 resin microspheres in chemotherapy refractory or intolerant patients with metastatic colorectal cancer

Silvia Coretti, Filippo Rumi, Dario Sacchini, Americo Cicchetti
- PDF
The offset effect of pharmaceutical innovation: A review study

Néboa Zozaya, Bleric Alcalá, Jhon Galindo
- PDF
A systematic review of economic evaluations in non-insulin antidiabetic treatments for patients with type 2 diabetes mellitus

Néboa Zozaya, Margarita Capel, Susana Simón, Alfonso Soto-González
- PDF

Point of View

Early Access in Oncology: Why Is It Needed?

Giovanni Apolone, Andrea Ardizzoni, Giuliano Buzzetti, Mario Alberto Clerico, Pierfranco Conte, Filippo de Braud, Francesco De Lorenzo, Maria Gabriella Ferrandina, Armando Genazzani, Stefania Gori, Michele Maio, Mauro Patroncini, Francesco Perrone, Giovanni Scambia, Giovanna Scroccaro
- PDF

Original Research Articles

Cost per responder for ixekizumab and other biologic drugs approved for the treatment of moderate-to-severe plaque psoriasis in Italy

Roberto Ravasio, Silvia Antonelli, Alessia Maiorino, Antonio Costanzo, Serena Losi
- PDF
Análisis del impacto presupuestario de alemtuzumab como terapia de segunda línea, en comparación con natalizumab y fingolimod, en pacientes previamente tratados con interferón beta 1b, diagnosticados con esclerosis múltiple remitente recurrente activa, tratados en la caja costarricense del seguro social

Luis Pastor Quirós, Rocío Ugalde
- PDF
Twenty Years of Hepatitis C in the Treviso District (Local Health Unit 2): Treatments, Clinical Management and Cost Analysis

Annachiara Bellin, Giulia Franchin, Jenny Bolcato, Alessandra Bettiol, Roberta Pirolo, Alberto Schiavon, Pietro Giusti, Michele Tessarin, Alessandro Chinellato
- PDF
The cost-effectiveness of alemtuzumab in the management of relapse-remitting multiple sclerosis in Italy

Sanja Stanisic, Antonio Bertolotto, Patrizia Berto, Paolo Di Procolo, Julia Morawski
- PDF
Severe haematological toxicities in relapsed ovarian cancer treated with olaparib or niraparib: an Italian cost-minimization analysis

Carlo Lazzaro, Nicola Amedeo Mazzanti, Fabio Parazzini
- PDF
The societal impact of treatment with natalizumab of relapsing–remitting multiple sclerosis in Italian clinical practice: The Tysabri® PharmacoEconomics (TyPE) Study

B Polistena, F Spandonaro, R Capra, S Fantaccini, L Santoni, GB Zimatore, C Gasperini
- PDF
Cost-effectiveness analysis of alectinib versus crizotinib in first-line treatment of anaplastic lymphoma kinase-positive advanced non-small cell lung cancer

Ravasio R, Tiseo M, Pradelli L, Bellone M, Gervasi A, Coffani M
- PDF
The economic impact of biosimilars in Italy: a scenario analysis

Francesco S Mennini, Andrea Marcellusi, Chiara Bini, Maria Assunta Rotundo, Alessandro Giunta, Antonio Gasbarrini, Guido Valesini, Pier Luigi Canonico, Ettore Novellino, Valentina Orlando, Alessandra Mecozzi, Teresa Gamucci, Livio Pagano, Eugenio Di Brino, Matteo Ruggeri, Americo Cicchetti
- PDF
Monitoring treatment response in metastasic colorectal cancer: Economic evaluation of PrediCTC versus computed tomography scan

Cristina Antón Rodríguez, Miguel Abal Posada, Lorena Alonso Alconada, Sonia Candamio Folgar, Rafael López López, Carlos Martín-Saborido
- PDF
Management of patients eligible for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: economic impact and reform proposals

Claudio Jommi, Marianna Cavazza
- PDF
Cost of illness of spinal muscular atrophy (SMA) in Italy

Andrea Marcellusi, Chiara Bini, Jacopo Casiraghi, Francesco D’Ambrosio, Maria A. Rotundo, Anita Pallara, Francesco S. Mennini
- PDF
Advanced-Metastatic Non-Small-Cell Lung Cancer EGFR-mutated in Italy: patient management costs and potential productivity losses

Nicola Amedeo Mazzanti, Carolina Scauri, Bianca Domini, Chiara Vassallo, Simone Cusato, Chiara De Fino, Filippo de Marinis
- PDF
Determining the value contribution of emicizumab (Hemlibra®) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis

Maria Teresa Álvarez-Román, Ignacio Cuervo-Arango, Rafael Pérez-Santamarina, José Luís Poveda, José Antonio Romero, Amparo Santamaría, José Luís Trillo-Mata, Marina Tort, Xavier Badia
- PDF

Review

Point of View

Original Research Articles

banners150